The effects of dexamethasone, cyclosporin A and prazosin were investigated in an animal model of retinal vasculitis. Both dexamethasone and cyclosporin A reduced the clinical and pathological signs of disease when given from the day of disease onset. Prazosin, an <XI adrenergic antagonist, was given during the period of disease induction and blocked fluorescein leakage from actively inflamed retinal vessels, but had little effect on the clinical and pathological signs of disease. This study demonstrates the feasibility of using this animal model for therapeutic trials of anti inflammatory agents in retinal vasculitis. The effect of prazosin on reducing vascu lar leakage from retinal vessels has implications for the treatment of inflammatory macula oedema in human disease.
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A number of animal models exist that closely resemble the various forms of human uveitis. In these animals, disease is induced by the inoculation of a purified heterologous retinal protein (such as retinal S-antigen) in Freund's complete adjuvant at a site distant from the eye. The nature of the disease produced depends on the species and strain of animal used, the dose of antigen and the adjuvants used with it.I,2 In all these models intraocular inflammation appears to be T-cell dependent, though humoral immunity may be involved in the initiation and regulation of disease. J These models have the potential for evaluat ing therapeutic regimes and for the develop ment of diagnostic tests for use in human disease. However, in the majority of cases therapeutic trials have used agents given during the induction of disease and have examined the subsequent modulating effects. 4.5,6,7 This approach has been necessary in order to explore the mechanisms involved in induction and also because, in the com monly used albino Lewis rat, disease is of sudden onset and short duration allowing insufficient time for the pharmacological action of the agents used. However, this is not strictly comparable to the treatment of human disease, where agents are given after disease onset.
In the present study we have used a model of retinal vasculitis in the black hooded Lister rat that shows striking similarities to human disease.8 This experimental disease may be serially observed using a fundus camera and lasts long enough to allow drugs given from the clinical onset of disease time to act. The presence of a pigmented retinal pigment epi thelium in the Lister rat allows effective fluor escein angiography so that the effects of drugs on inflammatory vascular leakage may be observed. We report the effect of the anti inflammatory drugs dexamethasone and cyclosporin A on the clinical, angiographic and pathological features of this disease when given from the day of disease onset. We also report the effect of prazosin, an (Xl adrenergic antagonist, on the modulation of these fea tures when given during the induction phase of disease. Figure 1 . Statistical significance derived using Student's t-test.
Material and Methods

Animals
were then observed for the appearance of specific clinical signs (disc oedema, deep retinal infiltrates), at which time they were killed.
Results
The results in the three groups of animals are summarised in Table III .
Clinical course of disease: There was no sig nificant difference in either day of onset or in duration of disease between the three groups of control animals. In both dexamethasone and cyclosporin A groups disease onset was similar in treated and control animals but the duration of disease was shortened by active treatment (this was not statistically signifi cant). The clinical disease score was reduced by treatment with both of these agents ( Fig. 1 ) once time had elapsed for their pharmacologi cal action (one day for dexamethasone, three days for cyclosporin A). Prazosin delayed disease onset by a week when compared with controls (p = 0.02; Student's t-test), but there was no significant difference in clinical scores between treated and control animals.
Fluorescein angiography: All animals in the dexamethasone and cyclosporin A groups showed fluorescein leakage from the disc and inflamed vessels; the steroid treated animals having a qualitative reduction in leakage when compared with their controls. Prazosin treated animals had less fluorescein leakage from swollen optic discs than did controls; moreover, 9/10 treated animals did not have leakage from clinically inflamed vessels (periphlebitis) or deep retinal infiltrates (Fig.  2) , whereas all control animals leaked from these peripheral lesions.
Histopathology: Histopathological features were scored according to Table II . Dex amethasone treated animals had a significant reduction in inflammatory cells in the vitreous and in the degree of perivasculitis and retinal destruction when compared with controls. Cyclosporin A treated animals had less infil tration of the vitreous and retina than did controls, and there was a trend towards a less marked retinal destruction. Prazosin treated animals and their controls had similar inflam matory infiltration and retinal destruction.
Discussion
In this study we have examined the modulat ing effect of three pharmacological agents on an animal model of retinal vasculitis. Disease in these animals comes on in the third week post-inoculation and may last up to fourteen days, thus allowing time for these agents to act during the expression rather than the induc tion of disease. Whilst both dexamethasone and cyclosporin A have been evaluated in terms of their effects on the induction phase of experimental uveitis in other models,4.5.6 they have not been extensively investigated during disease expression. 11 We also report the effect of prazosin, an (X l adrenergic antagonist, on reducing inflammatory vascular leakage in this model.
Steroids are the main drugs used in current clinical practice to control the inflammatory response in human retinal vasculitis. A major action of dexamethasone is to reduce Inter leukin-2 production by resting T-cells and thus to inhibit their proliferative response. 12 Dex amethasone was shown to reduce the clinical severity and pathological signs of experi mental uveitis in both this study and others. 5 . 11 However, the relevance of its anti-inflammatory action in experimental as compared to human disease is limited as the dose given is huge when translated into human terms, and steroids cause lysis of lymphocytes in rodents, rather than suppression which is seen in man. 13 Cyclosporin A is of known benefit in reduc ing those immune responses that are T-cell dependent in both experimental and human autoimmune disease.4.5,14 It is thought to act at several sites in the T-cell activation pro cessl 2 .15.16 and block proliferative responses. In this study cyclosporin A was effective in reducing the clinical and pathological signs of disease, this effect occurring three days after the start of treatment. Adequate levels of drug were achieved in the serum (data not shown) by intraperitoneal injection and there were no untoward effects on the health of animals. Cyclosporin reduced the clinical signs of disease three days after the onset of treatment and this was maintained through the rest of the study. No effect was seen on fluorescein leakage. Pathologically there was a reduction in vitreous infiltration and lym phocytic perivasculitis with a trend towards less marked retinal destruction. Thus cyclosporin A reduced clinical disease but ret inal destruction still occurred, suggesting that to be fully effective the drug should be given before the onset of disease, as noted by other authors. 5.1l Prazosin, a quinazoline derivative, is a specific (X l adrenergic antagonist used widely as an anti-hypertensive agent. Its use in this study was prompted by the reports of Brosnan et al. 17 .l8 who found that it reduced the clinical signs of experimental allergic encepha lomyelitis (EAE) by inhibiting inflammatory vascular leakage as determined by radiolabelled protein studies; this action being attributed to an inhibition of local vas oconstrictive events early in the establishment of delayed-type hypersensitivity (DTH) reac tions. It is thought that such events are medi ated through the release of vasoactive amines from local mast cells stimulated by IgE or factors released from activated antigen specific T-lymphocytes;19 these mediators increase vascular permeability allowing egress of serum proteins involved in subsequent inflammation. Prazosin-but not (X 2 (yo him- This study has shown that a model of retinal vasculitis in the black hooded Lister rat may be of practical importance in the assessment of anti-inflammatory drugs given from the onset of disease rather than during disease induction; this being the situation encoun-tered in clinical practice. Both dex amethasone and cyclosporin A reduced the clinical signs of disease in addition to attenuat ing the histological features of retinal inflam mation. Prazosin delayed the onset of disease and significantly reduced the fluorescein leak age from inflamed retinal vessels. As leakage of fluid from peripheTaI retinal vessels in human retinal vasculitis leads to macula oedema-a major cause of visual morbidity in this condition-prazosin may improve the visual prognosis: further studies to investigate this phenomenon are in progress.
